Fetal Hemoglobin Induction Compounds for Sickle Cell Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for sickle cell disease and beta-thalassemia, such as regular transfusions and bone marrow transplantation, come with significant side effects and limitations, while pharmacological induction of fetal hemoglobin (HbF) using agents like hydroxyurea has limited efficacy and side effects, necessitating the development of alternative compounds to induce endogenous embryonic/fetal globin expression.
Innovation Solution
Development of compounds, such as those of Formula (I), that induce the expression of endogenous embryonic/fetal globin chains, particularly γ globin, to treat anemia and related symptoms in sickle cell disease and beta-thalassemia, offering a potential alternative to existing treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If regular transfusion is used to replenish functional HbA, then survival requirement is met, but iron overload causing tissue damage and organ dysfunction occurs
Solution Approach 1:
The patent converts the harmful effect of excess alpha-globin chains (which cause toxicity and anemia) into a beneficial outcome by inducing fetal hemoglobin production. The gamma-globin chains from HbF pair with excess alpha-globin chains to form functional tetramers, transforming the toxic excess into useful functional hemoglobin and avoiding the need for iron-chelation therapy
Solution Approach 2:
The patent introduces fetal hemoglobin (HbF) as an intermediary substance that mediates between the excess alpha-globin chains and the need for functional hemoglobin. The gamma-globin chains act as intermediaries that can pair with alpha-globin chains, creating a bridge that resolves the incompatibility between excess alpha-chains and the requirement for balanced globin chain assembly
2Reliability
If bone marrow transplantation is performed to treat severe SCD and beta-thalassemia, then severe anemia can be cured, but identification of matched donor is limited and immune response risk increases
Solution Approach 1:
The patent enables the patient's own cells to produce the therapeutic agent (fetal hemoglobin) through pharmacological induction. The endogenous gamma-globin genes are reactivated in the patient's own erythroid cells, eliminating the need for external donor cells and avoiding all associated complexities of donor matching and immune rejection
3Reliability
If pharmacological induction of HbF using hydroxyurea is applied, then some efficacy is achieved, but limited efficacy and side effects remain
Solution Approach 1:
The patent employs a series of compounds with progressively optimized molecular parameters to induce gamma-globin expression. The compounds differ in their chemical structures (substituted benzylidene guanidines with various aromatic groups), and the invention selects compounds based on their ability to achieve higher HbF induction efficacy with improved safety profiles compared to hydroxyurea
Data Source
Figure 1A
Figure 1B
Figure 2~3
AI summary
Provided herein are compounds of Formula (I). The compounds described herein are useful in treating a disease associated with the expression of endogenous embryonic/fetal globin (e.g., γ globin) in erythrocytes (e.g., treating β -thalassemia and/or sickle cell disease through at least the induction of the globin gene expression in erythrocytes), and/or anemia (β-thalassemia and/or sickle cell anemia). The compounds described herein are useful in treating, delaying, and/or preventing the adverse effects of β-thalassemia and/or sickle cell disease, inducing γ globin production, and/or inducing the expression of embryonic/fetal globin genes in a subject, cell, tissue, or biological sample. Also provided in the present disclosure are pharmaceutical compositions, kits, and methods of using the compounds for inducing γ globin production described herein and for treating any of the target diseases described herein.